[go: up one dir, main page]

ZA200105062B - Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications. - Google Patents

Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications. Download PDF

Info

Publication number
ZA200105062B
ZA200105062B ZA200105062A ZA200105062A ZA200105062B ZA 200105062 B ZA200105062 B ZA 200105062B ZA 200105062 A ZA200105062 A ZA 200105062A ZA 200105062 A ZA200105062 A ZA 200105062A ZA 200105062 B ZA200105062 B ZA 200105062B
Authority
ZA
South Africa
Prior art keywords
amount
combination
nicotinic acid
compound
compounds
Prior art date
Application number
ZA200105062A
Other languages
English (en)
Inventor
Bradley T Keller
Kevin C Glenn
Daniel T Connolly
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200105062(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle Llc filed Critical Searle Llc
Publication of ZA200105062B publication Critical patent/ZA200105062B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200105062A 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications. ZA200105062B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23

Publications (1)

Publication Number Publication Date
ZA200105062B true ZA200105062B (en) 2002-08-28

Family

ID=22352512

Family Applications (5)

Application Number Title Priority Date Filing Date
ZA200105060A ZA200105060B (en) 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications.
ZA200105056A ZA200105056B (en) 1998-12-23 2001-06-20 Combinations for cardiovascular indications.
ZA200105059A ZA200105059B (en) 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications.
ZA200105061A ZA200105061B (en) 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications.
ZA200105062A ZA200105062B (en) 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications.

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ZA200105060A ZA200105060B (en) 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications.
ZA200105056A ZA200105056B (en) 1998-12-23 2001-06-20 Combinations for cardiovascular indications.
ZA200105059A ZA200105059B (en) 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications.
ZA200105061A ZA200105061B (en) 1998-12-23 2001-06-20 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications.

Country Status (23)

Country Link
US (1) US20040058908A1 (fr)
EP (2) EP1354604A1 (fr)
JP (1) JP2002533411A (fr)
KR (1) KR20020002367A (fr)
CN (1) CN1342091A (fr)
AR (1) AR037482A1 (fr)
AT (1) ATE248606T1 (fr)
AU (1) AU779264B2 (fr)
BR (1) BR9916564A (fr)
CA (1) CA2356515A1 (fr)
CZ (1) CZ20012344A3 (fr)
DE (1) DE69911058T2 (fr)
DK (1) DK1140187T3 (fr)
EA (1) EA200100704A1 (fr)
ES (1) ES2207330T3 (fr)
HU (1) HUP0104655A2 (fr)
IL (1) IL143944A0 (fr)
MX (1) MXPA01006468A (fr)
NO (1) NO20013157L (fr)
NZ (1) NZ512532A (fr)
PT (1) PT1140187E (fr)
WO (1) WO2000038725A1 (fr)
ZA (5) ZA200105060B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EP1110553B1 (fr) * 1998-08-10 2013-03-27 Asahi Kasei Pharma Corporation Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
EP1284723A4 (fr) * 2000-04-19 2004-06-30 Borody Thomas J Compositions et methodes pour traiter des troubles associes a l'hyperlipidemie
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
AU2007201970B2 (en) * 2001-01-26 2008-04-17 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CN1915429B (zh) * 2001-01-26 2010-12-15 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CN1582168A (zh) * 2001-01-26 2005-02-16 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
AU2006202618B2 (en) * 2001-01-26 2007-04-19 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1363668T1 (sl) * 2001-01-26 2007-12-31 Schering Corp Kombinacija sekvestranta(-ov) in zaviralca(-ev) absorpcije sterola ter zdravljenje vaskularnih indikacij
AU2006203175B2 (en) * 2001-01-26 2008-07-24 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
EP1389114A2 (fr) * 2001-03-08 2004-02-18 Merck & Co., Inc. Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
JP2005501861A (ja) * 2001-08-22 2005-01-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング １，４−ベンゾチエピン１，１−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用
NZ531292A (en) * 2001-08-22 2005-08-26 Aventis Pharma Gmbh Combination products of aryl-subsituted propanolamine derivatives with other active ingredients and the use thereof
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ES2278045T3 (es) 2001-09-08 2007-08-01 Astrazeneca Ab Derivados benzotiazepinicos y benzotiadiazepinicos con actividad inhibidora del transporte de acidos biliares del ileon (ibat) para el tratamiento de hiperlipidemia.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2460340C (fr) 2001-09-21 2011-02-15 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (ja) 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
CA2471639A1 (fr) * 2002-01-17 2003-07-31 Pharmacia Corporation Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate
US20030219401A1 (en) * 2002-03-18 2003-11-27 Keller Bradley T. Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
WO2003080118A2 (fr) * 2002-03-18 2003-10-02 Pharmacia Corporation Combinaison d'un antagoniste de recepteur d'aldosterone et de derive d'acide fibrique
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041288A1 (fr) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Therapie de remplacement d'hormone a l'aide de drospirenone
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
KR20050110017A (ko) 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2005061452A1 (fr) 2003-12-23 2005-07-07 Astrazeneca Ab Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol
DK1725234T4 (en) * 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
CA2553309A1 (fr) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Methode de gestion de la prise d'aliments
US7728015B2 (en) 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
CA2578224A1 (fr) * 2004-08-25 2006-03-09 Essentialis, Inc. Formulations pharmaceutiques d'activateurs de canaux potassiques atp, et utilisations correspondantes
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007047724A2 (fr) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Methodes de traitement de troubles associees l'hyperlipidemie chez un mammifere
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
WO2007081570A2 (fr) * 2005-12-30 2007-07-19 Merck & Co., Inc. Inhibiteurs de proteine de transfert des esters de cholesterol
EP1968601B1 (fr) 2006-01-05 2011-10-19 Essentialis, Inc. Sels d'ouvreurs des canaux potassiques atp-dépendants et leurs utilisations
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
EP2170341A4 (fr) * 2007-07-02 2010-12-01 Essentialis Inc Sels d'ouvreurs de canaux potassiques sensibles à l'atp et leurs utilisations
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
LT3400944T (lt) 2010-11-04 2020-09-25 Albireo Ab Ibat inhibitoriai, skirt kepenų ligų gydymui
BR112013010705B1 (pt) 2010-11-08 2020-11-17 Albireo Ab uso de um inibidor de ibat e um coagulante de ácido biliar, e formulação farmacêutica
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
SG11201401849QA (en) 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SG10201406155QA (en) 2011-10-28 2014-11-27 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
US8864587B2 (en) 2012-10-03 2014-10-21 Sony Corporation User device position indication for security and distributed race challenges
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
RU2015139731A (ru) 2013-03-15 2017-04-20 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US20150081210A1 (en) 2013-09-17 2015-03-19 Sony Corporation Altering exercise routes based on device determined information
US9269119B2 (en) 2014-01-22 2016-02-23 Sony Corporation Devices and methods for health tracking and providing information for improving health
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750944C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
EP3664782B1 (fr) 2017-08-09 2025-01-29 Albireo AB Pastilles de cholestyramine, formulations orales de cholestyramine et leur utilisation médicale
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PE20210136A1 (es) 2018-06-20 2021-01-21 Albireo Ab Formulacion farmaceutica de odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
SMT202300020T1 (it) 2019-02-06 2023-03-17 Albireo Ab Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3127408A1 (fr) 2019-02-06 2020-08-13 Albireo Ab Composes de benzothiazepine et leur utilisation en tant que modulateurs de l'acide biliaire
EP3923943B1 (fr) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Réponse dépendant du génotype et de la dose à un asbti chez des patients ayant une déficience de pompe d'exportation de sel biliaire
CN111789843A (zh) 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
EP4069361B1 (fr) 2019-12-04 2024-01-03 Albireo AB Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs de l'acide biliaire
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
WO2021110884A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothia(di)azepine et leur utilisation en tant que modulateurs d'acide biliaire
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
WO2021110886A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs de l'acide biliaire
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
WO2021110885A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothiadiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
EP4188372A1 (fr) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide destiné à être utilisé dans des méthodes de traitement de l'hyperlipidémie et de l'hypercholestérolémie chez des patients pédiatriques
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (fr) 2020-12-04 2022-06-09 Albireo Ab Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
EP4590307A1 (fr) 2022-09-19 2025-07-30 M2Sp Llc Traitement de l'insuffisance cardiaque à fraction d'éjection préservée avec de la guanéthidine et du guanadrel
WO2025146508A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire
WO2025146507A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) * 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3389144A (en) * 1965-06-08 1968-06-18 Mcneilab Inc 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols
US3287370A (en) * 1965-06-08 1966-11-22 Mcneilab Inc Tetrahydrobenzothiepins
US3444176A (en) * 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) * 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FR2077733B1 (fr) * 1970-02-10 1973-03-16 Roussel Uclaf
US3694446A (en) * 1970-02-24 1972-09-26 William J Houlihan 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4002750A (en) * 1972-04-28 1977-01-11 Carlo Erba S.P.A. Pyrazine 4-oxide derivatives and process for their preparation
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US3962261A (en) * 1974-02-04 1976-06-08 Warner-Lambert Company 2,3,4,5-tetra hydro-5-oxo-1-benzothiepi n-4-carboxamide 1,1-dioxides
FR2260569B1 (fr) * 1974-02-08 1978-06-16 Ugine Kuhlmann
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
SE420725B (sv) * 1974-09-26 1981-10-26 Ciba Geigy Ag Sett att framstella 2,3-dihydro-1-benstiepin-4-karboxylsyraamider
US4251526A (en) * 1977-10-31 1981-02-17 Mccall John M 2-Benzothiepins and compositions and methods of use therefore
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US5158943A (en) * 1988-11-21 1992-10-27 Takeda Chemical Industries, Ltd. Sulfur-containing heterocyclic compounds
US5153184A (en) * 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5075293A (en) * 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
AU664827B2 (en) * 1991-05-03 1995-12-07 Raisio Benecol Ltd. A substance for lowering high cholesterol level in serum and a method for preparing the same
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5519001A (en) * 1991-12-19 1996-05-21 Southwest Foundation For Biomedical Research CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
ATE135380T1 (de) * 1991-12-20 1996-03-15 Hoechst Ag Polymere und oligomere von gallensäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
FR2698873B1 (fr) * 1992-12-07 1995-02-24 Lipha Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
AU5538794A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Biologically active compounds and process therefor
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
TW289020B (fr) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289021B (fr) * 1993-05-08 1996-10-21 Hoechst Ag
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CN1084741C (zh) * 1994-09-13 2002-05-15 孟山都公司 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5705524A (en) * 1994-11-04 1998-01-06 Gilead Sciences, Inc. Thiepane compounds
US6034118A (en) * 1994-11-04 2000-03-07 Gilead Sciences, Inc. Thiepane compounds
EP0944602A1 (fr) * 1996-11-27 1999-09-29 Pfizer Inc. Amides inhibant la secretion d'apo b et/ou la proteine mtp
DE69815180T2 (de) * 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake

Also Published As

Publication number Publication date
EP1140187B1 (fr) 2003-09-03
AU2157700A (en) 2000-07-31
NZ512532A (en) 2003-12-19
ZA200105060B (en) 2002-09-20
DE69911058T2 (de) 2004-06-03
CN1342091A (zh) 2002-03-27
CZ20012344A3 (cs) 2002-01-16
ATE248606T1 (de) 2003-09-15
EA200100704A1 (ru) 2002-02-28
JP2002533411A (ja) 2002-10-08
EP1354604A1 (fr) 2003-10-22
DK1140187T3 (da) 2003-12-22
AU779264B2 (en) 2005-01-13
ZA200105061B (en) 2002-06-20
NO20013157L (no) 2001-08-22
WO2000038725A1 (fr) 2000-07-06
EP1140187A1 (fr) 2001-10-10
ZA200105056B (en) 2002-06-20
HUP0104655A2 (hu) 2002-04-29
CA2356515A1 (fr) 2000-07-06
KR20020002367A (ko) 2002-01-09
ZA200105059B (en) 2002-06-20
IL143944A0 (en) 2002-04-21
BR9916564A (pt) 2002-01-29
DE69911058D1 (de) 2003-10-09
US20040058908A1 (en) 2004-03-25
AR037482A1 (es) 2004-11-17
PT1140187E (pt) 2004-01-30
ES2207330T3 (es) 2004-05-16
NO20013157D0 (no) 2001-06-22
MXPA01006468A (es) 2004-03-10

Similar Documents

Publication Publication Date Title
ZA200105062B (en) Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications.
AU776953B2 (en) Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
AU776952B2 (en) Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
EP1140189B1 (fr) Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et de derives de l'acide fibrique utilisees dans le cadre de maladies cardio-vasculaires
CA2356422C (fr) Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle utilisees dans le cadre de maladies cardio-vasculaires
JP2005533810A (ja) 新規な抗コレステロール組成物及びその使用方法
JP2007091763A (ja) シトステロール血症の処置のための置換アゼチジノン化合物の使用
BRPI0612908A2 (pt) composições farmacêuticas compreendendo inibidores de absorção de colesterol à base de azetidinona e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
WO2007058335A1 (fr) Utilisation de tak-475 en association avec de l'ezetimibe dans le traitement de l'hyperlipidemie
ZA200105057B (en) Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications.
JP2008094852A (ja) 医薬
HK1058630A (en) Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications